Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
1.870
-0.090 (-4.59%)
At close: Mar 27, 2026, 4:00 PM EDT
1.870
0.00 (0.01%)
After-hours: Mar 27, 2026, 7:53 PM EDT
Ocugen Employees
Ocugen had 116 employees as of December 31, 2025. The number of employees increased by 21 or 22.11% compared to the previous year.
Employees
116
Change (1Y)
21
Growth (1Y)
22.11%
Revenue / Employee
$38,043
Profits / Employee
-$584,879
Market Cap
631.87M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 116 | 21 | 22.11% |
| Dec 31, 2024 | 95 | 30 | 46.15% |
| Dec 31, 2023 | 65 | -19 | -22.62% |
| Dec 31, 2022 | 84 | 28 | 50.00% |
| Dec 31, 2021 | 56 | 41 | 273.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 625 |
| Replimune Group | 479 |
| MeiraGTx Holdings | 409 |
| Arvinas | 246 |
| Prime Medicine | 146 |
| Alpha Tau Medical | 121 |
| Annexon | 99 |
| Jade Biosciences | 55 |
OCGN News
- 5 days ago - Ocugen, Inc. (OCGN) Discusses Top Line Results From Phase II ArMaDa Trial of OCU410 in Geographic Atrophy Transcript - Seeking Alpha
- 5 days ago - Ocugen Eye Disease Gene Therapy Data Trails Earlier Results, Stocks Falls - Benzinga
- 5 days ago - Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - GlobeNewsWire
- 6 days ago - Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy - GlobeNewsWire
- 25 days ago - Ocugen, Inc. (OCGN) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 25 days ago - Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 27 days ago - Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa - GlobeNewsWire
- 6 weeks ago - Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer - GlobeNewsWire